The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia

Acute coronary syndrome (ACS) in patients with essential thrombocytemia (ET). What is the best treatment?

(2016) G. Tortorella et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms

(2016) Luigi Gugliotta et al.   LEUKEMIA RESEARCH

Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide

(2015) Jiří Schwarz et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The gene expression signature of anagrelide provides an insight into its mechanism of action and uncovers new regulators of megakaryopoiesis

(2015) M. Ahluwalia et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms

(2015) Y. R. Espasandin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study

(2015) Giovanni Tortorella et al.   LEUKEMIA RESEARCH

Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia

(2014) G. Finazzi et al.   BLOOD

Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients

(2014) H. L. Geyer et al.   BLOOD

The importance of cardiovascular risk factors for thrombosis prediction in patients with essential thrombocythemia

(2014) Danijela Lekovic et al.   MEDICAL ONCOLOGY

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

(2013) H. Gisslinger et al.   BLOOD

Successful Long-Term Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms With Combination of Hydroxyurea and Anagrelide

(2013) Inhye E. Ahn et al.   Clinical Lymphoma Myeloma & Leukemia

Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France

(2013) Jérôme Rey et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Pharmacological management of essential thrombocythemia

(2013) Gunnar Birgegård   EXPERT OPINION ON PHARMACOTHERAPY

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study

(2013) L. Gugliotta et al.   HAEMATOLOGICA

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort

(2012) P. J. Campbell et al.   BLOOD

Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

(2012) T. Barbui et al.   BLOOD

Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up

(2012) Elisabeth Ejerblad et al.   Hematology

Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 – 50 years) and elderly (? 65 years) patients with essential thrombocythemia

(2012) Carlos Besses et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

(2012) Jan Palmblad et al.   International Journal of Medical Sciences

Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study

(2012) Carlos Besses et al.   LEUKEMIA RESEARCH

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients

(2011) R. Scherber et al.   BLOOD

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study

(2011) Tiziano Barbui et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria

(2011) G Finazzi et al.   LEUKEMIA

Low impact of cardiovascular adverse events on anagrelide treatment discontinuation in a cohort of 232 patients with essential thrombocythemia

(2011) Luigi Gugliotta et al.   LEUKEMIA RESEARCH

Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction

(2010) M. AHLUWALIA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Anagrelide for the Treatment of Thrombocythaemia in Daily Clinical Practice: A Post-Marketing Observational Survey on Efficacy and Safety Performed in Germany

(2010) Stephan Schmitz et al.   ONKOLOGIE

Pharmacokinetics, bioequivalence, tolerability, and effects on platelet counts of two formulations of anagrelide in healthy volunteers and patients with thrombocythemia associated with chronic myeloproliferation

(2009) Petro E. Petrides et al.   CLINICAL THERAPEUTICS

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia

(2008) A. Carobbio et al.   BLOOD

GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia

(2008) Ciro R. Rinaldi et al.   LEUKEMIA & LYMPHOMA